EGFR+ Lung Cancer

>

Latest News

FDA Approves Amivantamab/Chemo in Advanced EGFR Exon20Ins Mut+ NSCLC
FDA Approves Amivantamab/Chemo in Advanced EGFR Exon20Ins Mut+ NSCLC

March 1st 2024

Amivantamab plus carboplatin and pemetrexed is now an approved first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Osimertinib Enhances Progression-Free Survival in Stage III NSCLC
Osimertinib Enhances Progression-Free Survival in Stage III NSCLC

February 19th 2024

FDA Oks Osimertinib Plus Chemo in EGFR-Mutant Lung Cancer
FDA Oks Osimertinib Plus Chemo in EGFR-Mutant Lung Cancer

February 16th 2024

Worth The Wait? Genomic Testing Delays Initiation of Advanced NSCLC Therapy
Worth The Wait? Genomic Testing Delays Initiation of Advanced NSCLC Therapy

February 9th 2024

Osimertinib Combo Significantly Reduces CNS Progression in EGFRm NSCLC
Osimertinib Combo Significantly Reduces CNS Progression in EGFRm NSCLC

February 9th 2024

Video Series
Video Interviews
Podcasts

More News